StockData
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc (LGND) stock

LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)

Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –

Ligand Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Ligand Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2019 was 91.9%. For fiscal 2018 it was 97.5%, against 96.2% the year before. The highest annual figure on record is 97.5% in fiscal 2018.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2018Dec 31, 201897.5%+1.3
FY2017Dec 31, 201796.2%+1.3
FY2016Dec 31, 201694.9%+3.0
FY2015Dec 31, 201591.9%+6.1
FY2014Dec 31, 201485.8%−2.5
FY2013Dec 31, 201388.3%−0.2
FY2012Dec 31, 201288.5%+4.9
FY2011Dec 31, 201183.7%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2019Sep 30, 201987.3%−9.5
Q2 FY2019Jun 30, 201990.4%−8.4
Q1 FY2019Mar 31, 201991.1%−7.5
Q4 FY2018Dec 31, 201895.0%−2.0
Q3 FY2018Sep 30, 201896.8%+2.0
Q2 FY2018Jun 30, 201898.7%−0.3
Q1 FY2018Mar 31, 201898.6%−0.8
Q4 FY2017Dec 31, 201797.1%+4.7
Q3 FY2017Sep 30, 201794.8%–
Q2 FY2017Jun 30, 201799.0%–
Q1 FY2017Mar 31, 201799.4%–
Q4 FY2016Dec 31, 201692.4%–

More Ligand Pharmaceuticals figures

See a number that looks wrong?